We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.

Close

Investment Trusts

Seeking global value at a discount with Establishment

By Katie Morley , 23 May 2013

If you're looking for some cheap global growth for your portfolio take a look at this.

Seeking global value at a discount with Establishment

Recent articles

  1. Turning private equity risk into safer profits

    Turning private equity risk into safer profits

    By Leonora Walters | 23 May 2013

    Tim Spence and Emma Osborne tell Leonora Walters how it is possible to invest with a cautious approach in a high-risk area such as private equity and make good returns

  2. IC Top 100 Funds update: Polar Capital Technology Trust

    IC Top 100 Funds update: Polar Capital Technology Trust

    By Leonora Walters | 22 May 2013

    IC Top 100 Fund Polar Capital Technology Trust has not performed well recently, but its long-term numbers remain intact. So could a widening of its discount be an opportunity to buy, or are there better funds?

  3. Shares I Love: Pearson

    Shares I Love: Pearson

    By Moira O'Neill | 16 May 2013

    Nick Train, manager of Finsbury Growth & Income Trust, believes in a bull market in companies able to exploit digital technology.

  4. Why investment trusts beat open-ended funds

    Why investment trusts beat open-ended funds

    By Leonora Walters | 13 May 2013

    A look at the 'mirror funds' that have the same investment manager and strategy but different fund structures

  5. Healthy returns

    Healthy returns

    By John Baron | 10 May 2013

    After a strong start to the year relative to benchmarks, John Baron modestly rebalances both portfolios by increasing their bond exposure. Within equities, he also increases exposure to Japan and the pharma/biotech sector

Most read in Funds & ETFs

Advertiser reports

Register today and get...

Register today and get...